Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 36493 | 4.47 |
09:34 ET | 33177 | 4.47 |
09:36 ET | 5150 | 4.46 |
09:38 ET | 8079 | 4.441 |
09:39 ET | 8895 | 4.435 |
09:41 ET | 6981 | 4.43 |
09:43 ET | 8450 | 4.415 |
09:45 ET | 28099 | 4.41 |
09:48 ET | 39918 | 4.415 |
09:50 ET | 104503 | 4.45 |
09:52 ET | 278286 | 4.47 |
09:54 ET | 40257 | 4.47 |
09:56 ET | 22391 | 4.4946 |
09:57 ET | 1390 | 4.49 |
09:59 ET | 34650 | 4.495 |
10:01 ET | 9147 | 4.52 |
10:03 ET | 80328 | 4.515 |
10:06 ET | 6547 | 4.52 |
10:08 ET | 24282 | 4.5 |
10:10 ET | 10051 | 4.5001 |
10:12 ET | 16394 | 4.48 |
10:14 ET | 11313 | 4.495 |
10:15 ET | 30527 | 4.48 |
10:17 ET | 6123 | 4.485 |
10:19 ET | 33057 | 4.445 |
10:21 ET | 22559 | 4.465 |
10:24 ET | 29982 | 4.485 |
10:26 ET | 1300 | 4.48 |
10:28 ET | 227305 | 4.465 |
10:30 ET | 9870 | 4.47 |
10:32 ET | 3900 | 4.475 |
10:33 ET | 20197 | 4.465 |
10:35 ET | 13731 | 4.475 |
10:37 ET | 9701 | 4.48 |
10:39 ET | 12171 | 4.48 |
10:42 ET | 12658 | 4.465 |
10:44 ET | 6141 | 4.48 |
10:46 ET | 5488 | 4.475 |
10:48 ET | 9122 | 4.47 |
10:50 ET | 23642 | 4.465 |
10:51 ET | 38937 | 4.4601 |
10:53 ET | 33594 | 4.465 |
10:55 ET | 5753 | 4.4601 |
10:57 ET | 20213 | 4.48 |
11:00 ET | 7538 | 4.47 |
11:02 ET | 1429 | 4.475 |
11:04 ET | 6199 | 4.47 |
11:06 ET | 17631 | 4.46 |
11:08 ET | 16263 | 4.45 |
11:09 ET | 36817 | 4.46 |
11:11 ET | 8097 | 4.47 |
11:13 ET | 3442 | 4.46 |
11:15 ET | 14406 | 4.48 |
11:18 ET | 8355 | 4.475 |
11:20 ET | 5765 | 4.475 |
11:22 ET | 3541 | 4.475 |
11:24 ET | 17323 | 4.485 |
11:26 ET | 29357 | 4.47 |
11:27 ET | 1712 | 4.475 |
11:29 ET | 58936 | 4.475 |
11:31 ET | 7587 | 4.485 |
11:33 ET | 13375 | 4.4901 |
11:36 ET | 28094 | 4.49 |
11:38 ET | 15582 | 4.485 |
11:40 ET | 9270 | 4.495 |
11:42 ET | 3002 | 4.495 |
11:44 ET | 8189 | 4.505 |
11:45 ET | 6255 | 4.505 |
11:47 ET | 38916 | 4.49 |
11:49 ET | 12674 | 4.505 |
11:51 ET | 2420 | 4.51 |
11:54 ET | 15569 | 4.515 |
11:56 ET | 31215 | 4.515 |
11:58 ET | 4278 | 4.515 |
12:00 ET | 2452 | 4.515 |
12:02 ET | 9451 | 4.52 |
12:03 ET | 20446 | 4.525 |
12:05 ET | 13308 | 4.54 |
12:07 ET | 15978 | 4.535 |
12:09 ET | 31405 | 4.525 |
12:12 ET | 773 | 4.525 |
12:14 ET | 13220 | 4.535 |
12:16 ET | 8515 | 4.54 |
12:18 ET | 14506 | 4.54 |
12:20 ET | 15441 | 4.545 |
12:21 ET | 25406 | 4.535 |
12:23 ET | 1377 | 4.54 |
12:25 ET | 11329 | 4.525 |
12:27 ET | 10678 | 4.525 |
12:30 ET | 4445 | 4.53 |
12:32 ET | 6130 | 4.53 |
12:34 ET | 60746 | 4.52 |
12:36 ET | 14717 | 4.53 |
12:38 ET | 22394 | 4.5291 |
12:39 ET | 2611 | 4.52 |
12:41 ET | 48980 | 4.5 |
12:43 ET | 22431 | 4.516 |
12:45 ET | 12993 | 4.51 |
12:48 ET | 12483 | 4.5 |
12:50 ET | 184303 | 4.5 |
12:52 ET | 512863 | 4.475 |
12:54 ET | 37378 | 4.48 |
12:56 ET | 112990 | 4.49 |
12:57 ET | 15364 | 4.4793 |
12:59 ET | 12647 | 4.485 |
01:01 ET | 12730 | 4.48 |
01:03 ET | 10559 | 4.475 |
01:06 ET | 24338 | 4.47 |
01:08 ET | 20076 | 4.455 |
01:10 ET | 5938 | 4.455 |
01:12 ET | 641 | 4.45 |
01:14 ET | 17931 | 4.445 |
01:15 ET | 16616 | 4.435 |
01:17 ET | 3728 | 4.4356 |
01:19 ET | 4506 | 4.435 |
01:21 ET | 3711 | 4.435 |
01:24 ET | 11997 | 4.435 |
01:26 ET | 39763 | 4.415 |
01:28 ET | 5908 | 4.41 |
01:30 ET | 65339 | 4.41 |
01:32 ET | 28734 | 4.415 |
01:33 ET | 29963 | 4.425 |
01:35 ET | 8041 | 4.435 |
01:37 ET | 42658 | 4.41 |
01:39 ET | 4186 | 4.41 |
01:42 ET | 16427 | 4.405 |
01:44 ET | 14407 | 4.405 |
01:46 ET | 49818 | 4.405 |
01:48 ET | 112413 | 4.4 |
01:50 ET | 6589 | 4.405 |
01:51 ET | 1150 | 4.4 |
01:53 ET | 3335 | 4.405 |
01:55 ET | 6893 | 4.405 |
01:57 ET | 77142 | 4.415 |
02:00 ET | 4803 | 4.415 |
02:02 ET | 21567 | 4.41 |
02:04 ET | 38762 | 4.42 |
02:06 ET | 31697 | 4.42 |
02:08 ET | 35964 | 4.425 |
02:09 ET | 9652 | 4.415 |
02:11 ET | 5917 | 4.41 |
02:13 ET | 1700 | 4.415 |
02:15 ET | 29988 | 4.42 |
02:18 ET | 4536 | 4.425 |
02:20 ET | 16762 | 4.41 |
02:22 ET | 5758 | 4.415 |
02:24 ET | 7873 | 4.415 |
02:26 ET | 16185 | 4.41 |
02:27 ET | 4935 | 4.415 |
02:29 ET | 42615 | 4.415 |
02:31 ET | 4874 | 4.415 |
02:33 ET | 12381 | 4.41 |
02:36 ET | 499794 | 4.41 |
02:38 ET | 54542 | 4.425 |
02:40 ET | 26095 | 4.435 |
02:42 ET | 33594 | 4.435 |
02:44 ET | 24055 | 4.44 |
02:45 ET | 10319 | 4.445 |
02:47 ET | 28919 | 4.455 |
02:49 ET | 12401 | 4.455 |
02:51 ET | 18931 | 4.445 |
02:54 ET | 4080 | 4.44 |
02:56 ET | 3761 | 4.445 |
02:58 ET | 13797 | 4.455 |
03:00 ET | 27957 | 4.46 |
03:02 ET | 25862 | 4.454 |
03:03 ET | 15970 | 4.445 |
03:05 ET | 18075 | 4.455 |
03:07 ET | 22335 | 4.4537 |
03:09 ET | 452 | 4.455 |
03:12 ET | 18985 | 4.465 |
03:14 ET | 21597 | 4.45 |
03:16 ET | 18006 | 4.455 |
03:18 ET | 18548 | 4.44 |
03:20 ET | 8871 | 4.44 |
03:21 ET | 12913 | 4.43 |
03:23 ET | 22357 | 4.44 |
03:25 ET | 4921 | 4.445 |
03:27 ET | 6747 | 4.45 |
03:30 ET | 6932 | 4.445 |
03:32 ET | 32174 | 4.435 |
03:34 ET | 112054 | 4.435 |
03:36 ET | 6947 | 4.435 |
03:38 ET | 55685 | 4.415 |
03:39 ET | 9990 | 4.415 |
03:41 ET | 71796 | 4.415 |
03:43 ET | 9686 | 4.415 |
03:45 ET | 69899 | 4.415 |
03:48 ET | 57598 | 4.405 |
03:50 ET | 38921 | 4.425 |
03:52 ET | 131257 | 4.415 |
03:54 ET | 39351 | 4.405 |
03:56 ET | 124193 | 4.405 |
03:57 ET | 44599 | 4.4 |
03:59 ET | 1209173 | 4.43 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.7B | -12.3x | --- |
Iovance Biotherapeutics Inc | 2.8B | -5.6x | --- |
Immunitybio Inc | 2.6B | -3.8x | --- |
CG Oncology Inc | 2.5B | -31.6x | --- |
IDEAYA Biosciences Inc | 2.7B | -14.1x | --- |
Structure Therapeutics Inc | 2.5B | -18.9x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.7B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -12.3x |
Price/Sales (TTM) | 1,993.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.